Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes
NCT05569772 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 252
Last updated 2026-05-05
Summary
Gestational diabetes (GDM) is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who will develop T2DM within 5 years after the delivery. Moreover, women with a history of GDM progress more rapidly to T2DM compared to women with similarly elevated glucose levels. Early intervention after the index pregnancy is therefore crucial to prevent T2DM. With the SERENA project, the investigators aim to reduce the risk to develop T2DM with the long-acting GLP-1 agonist semaglutide in women with a recent history of GDM and glucose intolerance in early postpartum.
Conditions
- Glucose Intolerance After a Recent History of Gestational Diabetes
Interventions
- DRUG
-
Semaglutide Pen Injector
maintenance dose of 1mg SC once weekly
- DRUG
-
Semaglutide placebo
maintenance dose of 1mg SC once weekly
Sponsors & Collaborators
-
University Hospital, Antwerp
collaborator OTHER -
Universitair Ziekenhuis Brussel
collaborator OTHER -
General Hospital Groeninge
collaborator OTHER -
Onze Lieve Vrouw Hospital
collaborator OTHER -
Jessa Hospital
collaborator OTHER -
Ziekenhuis Netwerk Antwerpen (ZNA)
collaborator OTHER -
Vitaz
collaborator OTHER -
Centre Hospitalier Universitaire de Liege
collaborator OTHER -
Erasme University Hospital
collaborator OTHER -
Centre Hospitalier Mouscron
collaborator UNKNOWN -
Jan Yperman Ziekenhuis
collaborator OTHER -
AZ Turnhout
collaborator OTHER -
AZ Sint-Lucas Brugge
collaborator OTHER -
Universitaire Ziekenhuizen KU Leuven
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-09-14
- Primary Completion
- 2029-06-30
- Completion
- 2029-12-31
Countries
- Belgium
Study Locations
More Related Trials
-
Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"
NCT05305794 ·Status: RECRUITING ·Phase: PHASE3
-
ADJUnct Semaglutide Treatment in Type 1 Diabetes
NCT05537233 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Postprandial Incretin Response in Women With Gestational Diabetes
NCT01274052 ·Status: COMPLETED
-
The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes
NCT01795248 ·Status: COMPLETED ·Phase: PHASE4
-
Gestational Diabetes: Insulin or Oral Hypoglycemic Agents?
NCT01215331 ·Status: COMPLETED ·Phase: PHASE3
-
Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes
NCT04854083 ·Status: UNKNOWN ·Phase: PHASE4
-
Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes
NCT04324229 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Understanding Acute Dietary Changes After GLP-1 Agonist Treatment: The GLaD Feasibility Study
NCT07001553 ·Status: COMPLETED
-
The Effect of GLP-1 on the Inhibition of Glucagon Secretion
NCT01507597 ·Status: COMPLETED ·Phase: NA
-
A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes
NCT02212067 ·Status: COMPLETED ·Phase: PHASE1
-
Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes
NCT05597202 ·Status: UNKNOWN ·Phase: PHASE4
-
The Effect of Semaglutide on Cardiovascular Markers and Liver Function
NCT06301191 ·Status: RECRUITING
-
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)
NCT04261933 ·Status: COMPLETED
-
Blood Pressure Outcomes With Liraglutide Therapy
NCT01755572 ·Status: COMPLETED ·Phase: PHASE4
-
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)
NCT06774807 ·Status: COMPLETED ·Phase: NA
-
Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes
NCT01509742 ·Status: COMPLETED ·Phase: PHASE1
-
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
NCT06913023 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes
NCT04032197 ·Status: COMPLETED ·Phase: PHASE1
-
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
NCT03914326 ·Status: COMPLETED ·Phase: PHASE3
-
Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects
NCT02060266 ·Status: COMPLETED ·Phase: PHASE1
-
Insulin Sensitivity and Metabolomics During Oral Administration of Glucose and Graded Intravenous Infusion
NCT03223129 ·Status: COMPLETED ·Phase: NA
-
Semaglutide Treatment for Hyperglycaemia After Renal Transplantation
NCT05702931 ·Status: RECRUITING ·Phase: PHASE4
-
A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes
NCT05297045 ·Status: TERMINATED ·Phase: PHASE2
-
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
NCT02969798 ·Status: RECRUITING ·Phase: NA
-
Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes
NCT01363609 ·Status: COMPLETED ·Phase: NA